uniQure NV Reports 2025 Annual Results: Progress Amid Challenges in Gene Therapy
uniQure NV (NASDAQ: QURE), a pioneering biotechnology company specializing in gene therapy, has released its annual report for 2025, showcasing both advancements in clinical development and ongoing financial challenges. The report highlights the company’s commitment to delivering potentially curative treatments for rare diseases, while navigating complex regulatory landscapes and maintaining a strong financial position.
1. Overview of 2025 Developments
uniQure continues to solidify its position as a leader in the gene therapy sector, focusing on a targeted pipeline that includes promising candidates such as AMT-130 for Huntington’s disease and AMT-191 for Fabry disease. The company is also working on AMT-260 for refractory mesial temporal lobe epilepsy (MTLE) and AMT-162 for SOD1-ALS.
Huntington’s Disease Program (AMT-130)
The AMT-130 program has made significant strides, with the completion of enrollment for a third cohort of 12 patients and treatment of six patients in a fourth cohort. Positive topline data from the pivotal Phase I/II study was announced in September 2025, though subsequent discussions with the FDA indicated that further studies may be necessary to support a Biologics License Application (BLA) submission.
Other Clinical Candidates
In addition to AMT-130, uniQure has made progress with AMT-191 and AMT-260. The company completed treatment for all patients in the first cohort of AMT-260 and is currently enrolling for a second cohort. Meanwhile, AMT-191 has shown promising initial data in its Phase I/II trial.
2. Financial Performance
Revenue Breakdown
Despite advancements in its clinical pipeline, uniQure reported a modest revenue of $16.09 million for 2025, primarily driven by a 57.25% increase in license revenues, which totaled $15.93 million. However, collaboration revenues plummeted to $164,000, a stark decline attributed to reduced services requested by CSL Behring, and contract manufacturing revenues were recorded at $0, down from $6.1 million in 2024.
Income Statement Highlights
uniQure's net loss for 2025 was $198.9 million, a slight improvement compared to a $239.5 million loss in 2024. Operating expenses totaled $206.1 million, with $140.7 million allocated to research and development (R&D), reflecting a focus on advancing its clinical programs.
| Feb 2025 | Mar 2026 | |
|---|---|---|
Net Income | -239.5M | -198.9M |
Profit | -239.5M | -198.9M |
Net Income Continuing | -239.5M | -198.9M |
Income Tax Expense | 2.42M | 5.63M |
Pretax Income | -237.1M | -193.3M |
Non-operating Income | -52.83M | -7.99M |
Operating Income | -184.2M | -185.3M |
Revenue | 27.11M | 16.09M |
Other Operating Income | -4.57M | -8.04M |
Costs and Expenses | 214.7M | 207.8M |
Cost of Revenue | 1.26M | 1.68M |
Operating Expenses | 213.4M | 206.1M |
Research & Development | 143.7M | 140.6M |
Selling, General & Administrative | 52.65M | 65.45M |
Other Operating Expenses | 17.06M | 0 |
Balance Sheet Overview
As of December 31, 2025, uniQure's total assets amounted to $824.9 million, a significant increase from $556.5 million in 2024. The company's cash and cash equivalents stood at $622.5 million, bolstered by a series of successful financing activities throughout the year. Total liabilities reached $626 million, while equity totaled $198.9 million.
| Feb 2025 | Mar 2026 | |
|---|---|---|
Total Assets | 556.5M | 824.9M |
Total Current Assets | 390.2M | 655.9M |
Cash and Equivalents | 158.9M | 80.24M |
Short-term Investments | 208.5M | 542.3M |
Accounts Receivable | 5.88M | 5.86M |
Prepaid Expenses | 9.28M | 20.50M |
Other Current Assets | 7.60M | 7.07M |
Total Non-current Assets | 166.2M | 168.9M |
Intangible Assets | 93.45M | 98.14M |
Long-term Investments | 27.46M | 30.23M |
Non-current Deferred Tax Assets | 9.85M | 8.65M |
Net PP&E | 20.42M | 13.8M |
Lease Assets | 13.64M | 12.52M |
Other Non-current Assets | 1.39M | 5.56M |
Total Liabilities and Equity | 556.5M | 824.9M |
Total Liabilities | 563.2M | 626.0M |
Total Current Liabilities | 40.05M | 62.91M |
Accounts Payable and Accrued Liabilities | 36.45M | 46.46M |
Current Debt | 3.60M | 3.86M |
Other Current Liabilities | 0 | 12.59M |
Total Non-current Liabilities | 523.2M | 563.0M |
Long-term Debt | 51.32M | 49.69M |
Non-current Deferred Tax Liabilities | 7.04M | 7.96M |
Other Non-current Liabilities | 464.8M | 505.4M |
Total Equity and Non-controlling Interests | -6.75M | 198.9M |
Total Equity | -6.75M | 198.9M |
Cash Flow Statement Insights
The company reported a net change in cash of -$78.52 million for the year, driven by heavy investment activities totaling -$321.6 million. However, financing activities generated $415.3 million, primarily from public offerings, enhancing the liquidity position significantly.
| Feb 2025 | Mar 2026 | |
|---|---|---|
Net Change in Cash | -84.21M | -78.52M |
Effect of Exchange Rate Changes | -4.96M | 5.65M |
Net Cash from Operating Activities | -182.7M | -177.9M |
Operating Profit | -239.5M | -198.9M |
Adjustment to Operating Profit | 56.82M | 21.00M |
Net Cash from Investing Activities | 162.9M | -321.6M |
Business & Interest in Affiliates | -8.32M | 0 |
Investments | -174.6M | 321.1M |
Productive Assets | 3.36M | 439K |
Other Investing Activities | -16.64M | 0 |
Net Cash from Financing Activities | -59.48M | 415.3M |
Debt | -53.05M | 0 |
Equity Issuance/Repurchase | 2.12M | 34.66M |
Other Financing Activities | -8.55M | 380.7M |
3. Financing Activities
2025 was marked by significant financing initiatives, including a $70.1 million follow-on public offering in January, followed by an additional $10.4 million from underwriters’ options. A major follow-on public offering in September raised $323.7 million, and the establishment of a $175 million senior secured term loan facility with Hercules provides further financial flexibility.
4. Conclusion
uniQure NV is poised to continue its pursuit of innovative gene therapies as it navigates a challenging landscape characterized by regulatory scrutiny and the need for additional studies. With a robust liquidity position and a strong pipeline, the company remains committed to its mission of providing transformative treatments for patients with rare diseases. However, the pathway to commercial success for its lead candidate, AMT-130, remains complex, requiring ongoing investment and strategic planning.
As the company looks ahead, the need for additional funding remains a consideration, particularly if the BLA for AMT-130 is not approved by mid-2027. Investors and stakeholders will keenly watch how uniQure addresses these challenges while leveraging its financial resources and clinical advancements.
